Breast Cancer - Is There a Survival Benefit Emerging?

Abema has shown statistically significant overall survival in the second line metastatic setting. My strategy would be use ribosic lip and then maybe if these trials also provide that confirmation. Think about utilizing abema as a second line approach. Getting so many questions in the chat room. We'll never get through all the will have to deal with these and the other ones as well. Fadi, you got a patient with let me see if I can find it here. Okay, triple negative breast cancer gets new agent therapy. It doesn't say whether or not Pembro also, but as a path CR. But I guess has a Braca germline mutation. So would you give a